Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of insolvency and Novartis hired a new top lawyer.

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

New passenger car registrations in Croatia declined by 3.4% on the year in the first two months of 2025, to 8,717, the European Automobile Manufacturers Associa ...

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front ...

Wall Street's major averages closed in the green on Friday, and the benchmark S&P 500 (SP500) snapped a four-week losing streak after U.S. President Donald Trump said there might be some "flexibility" ...

On June 5, 2024, two experienced NASA astronauts went to the International Space Station (ISS) for an eight-day test flight. But things didn’t go as planned. A series of unexpected problems left ...

For Sanofi, SanofiTV is the company’s primary global social media tool, and it has its own Twitter channel too. So I considered this as Sanofi’s global Twitter account, even though it has ...

Sanofi is acquiring private biotech, Dren Bio’s targeted bispecific myeloid cell engager (MCE), DR-0201 for an upfront payment of $600 million. In clinical studies, DR-0201 has shown robust B ...